Navigation Links
Halozyme Secures Additional $20 Million Term Loan
Date:1/6/2014

SAN DIEGO, Jan. 6, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced it secured an additional $20 million loan from Oxford Finance and Silicon Valley Bank.  On December 27, 2013, Halozyme entered into an Amended and Restated Loan and Security Agreement, extending the original $30 million term loan and providing for an additional $20 million term loan, bringing the total loan balance to $50 million.  The term loan was fully drawn at close on December 27, 2013 and has a maturity date of January 1, 2018.  The proceeds will be used for working capital and other near-term growth initiatives.  Additional details of the credit facility are outlined in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 3, 2014.  As of December 31, 2013, Halozyme had approximately $71 million in cash and cash equivalents.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com and follow us on Twitter @HALOTherapeutic.

Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the use of cash from its additional term loan) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2013.

Investor Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies
310-633-9434
Nurha.Hindi@hkstrategies.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Portfolio Expansions, Product Data, and Announcements by Healthcare Companies - Research Report on Life Technologies, OncoMed, Halozyme Therapeutics, Infinity, and PTC Therapeutics
2. Halozyme Therapeutics Announces Executive Transitions
3. Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
4. Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
5. Halozyme to Host Third Quarter 2013 Financial Results Conference Call
6. SWOG Initiates Randomized Phase 2 Clinical Trial of Halozymes PEGPH20 in Combination with modified FOLFIRINOX for Advanced Pancreatic Cancer
7. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
8. Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche
9. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
10. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
11. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... April 18, 2017 Research and Markets has ... report to their offering. ... The global arthroscopy devices market to grow at a CAGR of ... Arthroscopy Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:4/18/2017)...  Socionext Inc. and SOINN Inc. today announced ... which Socionext extracts and delivers biometrics data to ... results in reading ultrasound images from Socionext,s viewphii™ ... results will be introduced at Medtec Japan, held ... 4505 & 4507. In this initial ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 26, 2017 , ... New SUPRO® XT55 Isolated Soy ... by helping beverage manufacturers more effectively manage protein costs. “Soy protein has always ... well as more stable pricing over time. Now it’s even more relevant as ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop Inc. ... Pro . This new addition to the Mirroring360 product family combines device screen ... , Mirroring360 Pro enables educators, business professionals and individuals to stream or mirror ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President ... are preparing for how his administration could impact the employee benefits industry. James ... changes are most likely to make it through Congress. His discussion will focus ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients who would like ... in a fraction of the time as traditional braces – Wilckodontics®. Dr. Victoria ... now offers this revolutionary treatment with or without a referral. , Wilckodontics ...
(Date:4/25/2017)... ... , ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – ... but be heartened by the industry’s current surge. But another thing that unifies them ... At last they can simply, safely and effectively end their aroma anguish thanks ...
Breaking Medicine News(10 mins):